Tim Smith has joined Verseau Therapeutics as its chief business officer. Smith’s experience includes business development roles at Dova Pharmaceuticals, IDEAYA Biosciences (NASDAQ: [[ticker:IDYA]]), Cleave Biosciences, and Celgene (NASDAQ: [[ticker:CELG]]). Bedford, MA-based Verseau is developing a type of cancer immunotherapy called macrophage checkpoint modulators. Last month, the company closed $50 million in Series A financing.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
